Immunitrack together with CCIT receive Eurostars funding for a novel prediction tool to enhance cancer vaccine performance and help monitor patients’ immune responses during novel drug development
Immunitrack ApS (‘Immunitrack’), a privately-held biotechnology company focused on immunogenicity prediction and assessment of new vaccines and biotherapeutics, announces the successful approval of a Eurostars grant application, in a consortium CCIT Herlev Hospital. The grant award is approximately €750,000, covering a 24-month period, of which Immunitrack can expect to receive in the order of €395,000.
The project aims to develop a novel T-cell epitope prediction software, called PrDx, which, when combined with currently commercialised reagents and assay services, will represent a very powerful epitope (neoantigen) identification platform. The project focus is cancer, with the software development conducted by Immunitrack and in vitro validation performed by CCIT. Clinical validation is expected to be carried out in melanoma patients. These studies will help us characterize immune responses to specific neoantigens, helping to understand what drives anti-tumour immunity using novel vaccines based on these neoantigens and, for example, in the context of combination treatment with checkpoint inhibitors. The outcome of the validation process should also serve as proof of concept for other applications, such as de-immunisation of biologics.
The Eurostars grant
Eurostars supports international innovative projects led by research and development- performing small- and medium-sized enterprises (R&D-performing SMEs). With its bottom-up approach, Eurostars supports the development of rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world. Eurostars is a joint programme between EUREKA and the European Commission, co-funded from the national budgets of 36 Eurostars Participating States and Partner Countries and by the European Union through Horizon 2020. In the 2014-2020 period it has a total public budget of €1.14 billion. Read more about Eurostars here >
About CCIT Herlev Hospital
The overall aim of CCIT (Center for Cancer Immune Therapy, based in Herlev, Denmark) is to significantly improve our ability to bridge the gap between discovery and clinical implementation in the field of cancer immunotherapy. CCIT is focused on the development of the immunological treatment of cancer, with a research profile based on complementary experimental and clinical projects. In 2017 CCIT was appointed national research and competence center for immunotherapy.
For further information, please contact:
Stephan Thorgrimsen, CEO